Guidance ledger · Q4 FY26

Aurobindo Pharma Ltd AUROPHARMA

5 revisions on record · 0 lowered · 3 raised — the strikethrough is what management used to say

gives specific guidance · shifted across quarters

Holding view → · latest concall · The pulse

↑ raised EBITDA margin (FY26 -> forward) Q1 FY26 → Q4 FY26

~~20%-21% range (Q1FY26 maintained through Q3)~~ → north of 21%

“expect EBITDA margins to sustain and progressively improve to north of 21%, reflecting”

→ narrowed Europe annual revenue milestone Q1 FY26 → Q4 FY26

~~EUR 1 billion by end of FY26 (Q1 forward call)~~ → EUR 1 billion delivered; FY27 minimum double-digit growth on top

“significant milestone of €1 billion revenue in terms of annual revenues”

↑ raised US revenue ambition Q1 FY26 → Q4 FY26

~~no explicit number (Q1-Q3 framed defensively around destocking and Lannett)~~ → $2 billion target over near term (1-2 years per Swami)

“is aiming to touch the $2 billion revenue milestone over the near term”

→ narrowed Pen-G annualised production Q1 FY26 → Q4 FY26

~~50-60% utilisation, healthy EBITDA from Q3 (Q1 ask)~~ → exceed 10,000 MT, >80% utilisation, ~Rs.100cr+ external sales already booked

“exceed 10,000 metric tons with a capacity utilization level exceeding 80%”

↑ raised Biosimilars 2030 platform Q1 FY26 → Q4 FY26

~~EU launches starting Q3-Q4 with above-average EBITDA (Q1)~~ → 7-8 EU/growth + 2-3 US by 2030, $450m cumulative investment disclosed

“we are looking at biosimilars business having 7 -8 products in Eu rope and growth markets,”

Method. Revisions come from management's own stated numbers, compared quarter over quarter across the covered concalls; each carries the verbatim quote. “No revisions” can also mean guidance too vague to pin down — see the posture chip above. Not investment advice.